Realm Therapeutics is a biopharmaceutical company that focuses on developing immunomodulatory therapies for the treatment of dermatology and ophthalmology diseases. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis, and PRO13, a topical ophthalmic solution that is initiation Phase IIb clinical trial for the treatment of allergic conjunctivitis.